COVID-19 Impact on Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas

Dublin, April 24, 2020 (GLOBE NEWSWIRE) — The “COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas” report has been added to ResearchAndMarkets.com’s offering.
For years, the analyst has covered the fields of molecular diagnostics, immunoassays, vaccines, and telehealth – these all find themselves both sought-after and challenged during the current COVID-19 crisisThis report provides trending developments, company announcements, and analysis from the analysis team on the fast-breaking events in the COVID-19 epidemic.Particular sections address the most important market changes:Molecular Diagnostics: It’s important to note that the entire molecular testing concept originated in the midst of a crisis, at that time of the AIDS crisis, and has since been brought to bear on a number of emerging and mature infectious disease categories. COVID-19 has seen the molecular in vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndromic tests, high throughput systems and surge production on badly needed kits.Immunoassays: Never have immunoassays been of such worldwide attention, as antibody tests are greatly sought. With this, come concerns about accuracy levels on broad populations and greater knowledge about development times. There are now immunoassays in development. We track these efforts and provide commentary on the role of these tests in a threat so far dominated by molecular diagnostics.Vaccines: The analyst look at the vaccines in development and the struggles with vaccine discovery and manufacturing in other pandemics. Companies developing vaccines are featured.Other Traditional IVDs: With many hospitals shut down across the globe, what is the impact and expected future of standard in vitro diagnostic testing? – from company statements made both publicly and directly to the analyst.Remote Patient Monitoring: Already a healthcare trend that was catching on but perhaps struggling to convince payors of its critical necessity, remote patient monitoring, and telehealth transformed overnight with social distancing policies and relaxed HIPAA rules. But will market players be crowded out by traditional phone and web video companies?This report does not seek to provide a data-driven market assessment due to the rapidly-changing situation but does provide analyst commentary that may assist customers needing to work out models. Some of the market estimates provide foundational bases on which to judge potential market impact. Commentary and analysis from the analysts who have studied markets in some cases for decades add understanding to the current, often chaotic, market atmosphere. Further publications and surveys from the analyst will provide additional market impact data.No one company has the solution to COVID-19. Multiple companies have solutions to one problem or part of the solution, and companies are partnering to build strength and distribute products.Key Topics Covered
Chapter One: SARS-Cov-2 Recent DevelopmentsMolecular Testing, So Far, Remains At ForefrontAntibody SARS-Cov-2 Tests Move ForwardOverall Diagnostics Testing Taking a HitWhen Will Surgeries – and Related Diagnostic Testing – Resume?Asymptomatic and Presymptomatic Spread Will Focus Attention on TestingContinuous Introduction and Authorization of New Test ProductsMolecular DXImmunoassaysSpain Provides Example of Downside of Early Serology TestAncillary/Secondary Covid-19-Related TestsU.S. Government ResponseCongress Passes Cares ActHHS Awards $100M to Deal With Coronavirus, Including TestingBarda Funding for POC, Panels and Automated TestsWhite House Pushes DiagnosticsCovid-19 Threat Makes for Odd Timing of Valid ActBackgroundDefining SARS-Cov-2Naming the VirusOrigins of SARS-Cov-2A Unique Molecular BackboneFDA Provides Reference Sequence Data for SARS-Cov-2Countermeasures in DevelopmentWill We See Fundamental Change in IVD?Chapter Two: Molecular Diagnostics and SARS-Cov-2The Molecular Diagnostics Industry is Large and CapableRapid Ramp Up After Early StumblesFast EUAs as FDA Moves to Speed Availability of Covid-19 TestsTwist’s SARS-Cov-2 Quality Controls Added to FDA MaterialsTest ApprovalsTable: US FDA EUAs as of April 1, 2020Mesa Handheld Mdx Test ShipsSyndromic Approach to Covid-19: QiagenAbbott Id Now Becomes National Symbol of Poc ResponseLuminex Coronavirus Panel Gets FDA Emergency AuthorizationBGI Gets EUA for Rt-PCR Coronavirus TestQuidel Receives Expanded ApprovalNeumodx Coronavirus Test Gets Emergency AuthorizationT2 Adds Coronavirus Test to Panels, Per Health Network DealPerkinelmer Gets Regulatory Nod in the U.S. for Coronavirus TestRoche Offers Multiple Commercial KitsThermo Fisher Gets CE Mark for the Taqpath Covid-19 Rt-PCR Test KitMesa Biotech Gets Emergency Authorization for Poc Coronavirus TestFluxergy Seeks Emergency Authorization for 1-Hour Coronavirus TestGenetic Signatures Seeks CE Mark for Coronavirus DiagnosticEmerald Organic, Todos Medical Team on Covid-19 TestsBruker, Primer Design Sign European Distribution Deal for Coronavirus TestImpact of Large Systems and Small Poc SystemsMolecular Point of CareMolecular POC Vs. ImmunoassaysChapter Three: BottlenecksPractical Challenges and Scaling of Test ResourcesTest Equipment and Worker Ppe Remain An IssueJama Network Calls for Creative Ideas for Increasing Ppe SupplyWhy SARS 2.0 is More Difficult to ControlTable: Covid-19 Case Severity ScaleSARS-Cov-2 Replication in Upper Respiratory Track Seen as CulpritHais a Worryare Coronavirus Patients With Negative Throat Swabs Truly Virus-Free?Patients May Continue to Shed Virus After Symptom ClearanceViral Load/ Symptom Connection: Conflicting StudiesMPOC S are Approved; Full Impact Yet to Be SeenFigure: FDA EUA Tests for Covid-19 by Testing TypeQiagen Says It Ramped Up Production to Meet Shortage of Rna Extraction KitsChapter Four: Covid-19 ImmunoassaysAntibody-Based Testing Taking ShapePolicy D PathwayCEllex ApprovalBiomedomicsGetting Better Guidance on Test QualitySerology Test NotificationsChapter Five: Other Test Categories Impact: Critical Care, ChemistriesCritical Care AnalysisBlood GasCritical Care Analytes: Bilirubin, Bun, GlucoseOther Covid-19-Related TestsAKI TestingChapter Six: Vaccines and SARS-Cov-2Early Efforts and a First Trial DoseJ&J Seeks to Release Covid-19 Vaccine by 2021Dod Grant Accelerates SARS-Cov-2 Vaccine ManufacturingDynavax, Clover Partner for Protein-Based Covid-19 VaccineAnalysts: Technology, Not Demand ChallengeProduction Consideration3D Atomic Scale Map Could AId VaccinesChapter Seven: Boost for Remote Patient Monitoring Seen in SARS-Cov-2 CrisisCongressional ActionHippa Penalties RelaxedUnique Opportunities in Telehealth/TelemedicineCompanies in the MarketRecent DevelopmentsChapter Eight: a Role for Artificial Intelligence (AI)IntroductionWhite House Urges Researchers to Use AI to Analyze Coronavirus PapersDiagnostic ApplicationsSouth Korean Firm Blends AI and Portable X-Ray Testing to Power Up Covid-19 PCRPersivia Releases AI-Driven Ruleset to Detect Covid-19Philips Intellisite Pathology SolutionSurgisphere Rapid Test Uses AI to Diagnose Covid-19Biofourmis’ AI-Powered Remote Monitoring Platform to Fight Covid-19AI as An AId in the Development of Covid-19 TherapiesChapter Nine: Therapeutics and Covid-19FDA’s Coronavirus Treatment Acceleration Program (Ctap)Snapshot for Developing TherapeuticsExamples of CTAP in ActionSupport for CTAPSelected Therapeutic ApproachesDrug RepurposingCar-T Support Therapeutic Finds Possible Use in Covid-19Kleo, Green Cross Collaborate on Covid-19 Nk Combination TherapyGeneration Bio, Vir Partner for Mabs Against Covid-19Xencor, Vir Partner on Covid-19 Antibodies ResearchFrontera Supercomputer AIds Covid-19 Drug DevelopmentHydroxychloroquineChapter Ten: Respiratory Equipment in Extreme DemandVentilatorsCPAP Devices and Covid-19 Patient UsageCPAP as an Emergency Ventilator?Risk of Virus Spread and Possible SolutionsPulse OximetersRecent EU ActivityCares ActDefense Production ActChapter Eleven: Research Laboratory Operations ImpactedNIH Shifts Noncritical Research to MaintenanceSurvey: Nearly Half of All Life Science Labs Around the World are Currently ClosedSurvey: Covid-19 Causes Long-Term Disruptions to Clinical TrialsCompanies Mentioned
AbbottAmaro Lab of the University of California (UC), San DiegoAvellino Lab USABGIBioFireBiofourmisBoston ScientificBrukerCepheidCloverCredo Diagnostics BiomedicalDiagnostics for the Real WorldDiaSorin MolecularDynavaxEmerald OrganicEpiGentekFluxergyGE HealthcareGeneration BioGenetic SignaturesGenMark DiagnosticsGilead ScienceGreen CrossHackensack Meridian Health, Center for Discovery and Innovation’s (CDI)Henry ScheinHiberGene DiagnosticsHologicJLK InspectionJohnson & Johnson (J&J)KleoLaboratory Corporation of America (LabCorp)LuminexMedtronicMesa BiotechMobidiagMolbio DiagnosticsNeuMoDxPerkinElmerPersiviaPhilips MedicalPrimer DesignQiagenQuantuMDxQuestQuidelRocheSurgisphereT2 BiosytemsThermo FisherThermoGenesisTodos MedicalVirWadsworth Center, New York State Department of HealthXencorFor more information about this report visit https://www.researchandmarkets.com/r/1anzkzResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900